Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/15/2018 |
| Start Date: | June 2014 |
| End Date: | February 2019 |
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination With TGR-1202, a Novel PI3K Delta Inhibitor, in Patients With Hodgkins Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in
combination with brentuximab vedotin in patients with hodgkin's lymphoma.
combination with brentuximab vedotin in patients with hodgkin's lymphoma.
Inclusion Criteria:
- Confirmed diagnosis of Hodgkin's Lymphoma
- Relapsed or refractory after an autologous stem cell transplant (ASCT) or at least two
prior multi-agent chemotherapy regimens in patients not candidates for ASCT
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria:
- Any major surgery, chemotherapy or immunotherapy within the last 21 days
- Known hepatitis B virus, hepatitis C virus or HIV infection
- Autologous hematologic stem cell transplant within 3 months of study entry. Patients
who had prior Allogeneic hematologic stem cell transplant are excluded
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials